Diabetic kidney disease
Premium quality or just over-priced? How affordable are the PCSK9 monoclonal antibodies?
Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses recent economic analyses from the US and UK. Cardiovascular disease (CVD) remains one of the commonest causes of morbidity and mortality in the world. The epidemiology of CVD is changing as rates of smoking decrease but…read more »
Posted on 13 September 2016 | Posted by Anthony Wierzbicki | Posted in News, From the Editors
PCSK9 levels in diabetic kidney disease
PCSK9 levels did not appear to be influenced by the extent of renal dysfunction or albuminuria in this cross-sectional study in patients with diabetic kidney disease. Diabetic kidney disease is one of the key drivers of escalating morbidity and mortality due to chronic kidney disease…read more »
Posted on 10 August 2016 | Posted in News